Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
22.18 ^USD	-0.81%		-5.94%	+22.68%

May. 06	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
May. 02	European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	MT

Bicycle Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 03, 2023 at 07:14 am EDT

Bicycle Therapeutics plc reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 42.6 million compared to USD 26.83 million a year ago. Basic loss per share from continuing operations was USD 1.41 compared to USD 0.9 a year ago.
For the six months, net loss was USD 81.67 million compared to USD 54.39 million a year ago. Basic loss per share from continuing operations was USD 2.71 compared to USD 1.84 a year ago.

Latest news about Bicycle Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	May. 06	MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading	May. 02	MT
Bicycle Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Bicycle Therapeutics plc Announces Promotion of Mike Hannay as Chief Product and Supply Chain Officer	May. 02	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	Apr. 26	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
Bicycle Therapeutics plc Announces Board Changes	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Q32 Bio Appoints Lee Kalowski as President	Apr. 03	CI
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
Transcript : Bicycle Therapeutics plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:30 AM	Mar. 14
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading	Feb. 27	MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading	Feb. 26	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Feb. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 21	MT
HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating	Feb. 21	MT
Bicycle Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Bicycle Therapeutics Appoints Stephen Sands to the Board of Directors	Feb. 20	CI
Bicycle Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Feb. 15	MT

Chart Bicycle Therapeutics plc

Duration

Period

More charts

Company Profile

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 3088

More about the company

Income Statement Evolution

More financial data

Ratings for Bicycle Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.18 USD

Average target price

44 USD

Spread / Average Target

+98.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BICYCLE THERAPEUTICS PLC	+22.68%	954M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs